

# KSHV ORF 72 (vR-15): sc-19415

## BACKGROUND

Human herpesvirus 8 (HHV8, Kaposi's sarcoma-associated herpesvirus (KSHV) ORF 72 (v-cyclin, cyclin D homolog) is a viral homolog to mammalian cyclin D. ORF 72 (v-cyclin) has the potential to affect the activity of the retinoblastoma protein (Rb) by eliciting p16INK4a resistant Cdk activity. Viral cell homologs are expressed at particular times during the lytic process. Expression of several viral cellular gene homologs, including ORF 72 (v-cyclin), is unaffected by the presence of cidofovir (CDV), a nucleotide-analogue KSHV DNA polymerase inhibitor. KSHV is associated with the endothelial tumor Kaposi's sarcoma (KS) and lymphoproliferative disorders in immunocompromised individuals. KSHV may stimulate and maintain abnormal plasma cell proliferation in myeloma and related disorders.

## REFERENCES

1. Munker, R., et al. 1997. HHV-8 (KSHV) does not establish latency in prostate cancer cell lines. *Prostate* 33: 286-288.
2. Chauhan, D., et al. 1999. Detection of Kaposi's sarcoma herpesvirus DNA sequences in multiple myeloma bone marrow stromal cells. *Blood* 93: 1482-1486.
3. Raje, N., et al. 1999. Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences. *Blood* 93: 1487-1495.
4. Raje, N., et al. 2000. Kaposi's sarcoma-associated herpesvirus gene sequences are detectable at low copy number in primary amyloidosis. *Amyloid* 7: 126-132.
5. Grundhoff, A., et al. 2001. Mechanisms governing expression of the v-FLIP gene of Kaposi's sarcoma-associated herpesvirus. *J. Virol.* 75: 1857-1863.
6. Low, W., et al. 2001. Internal ribosome entry site regulates translation of Kaposi's sarcoma-associated herpesvirus FLICE inhibitory protein. *J. Virol.* 75: 2938-2945.
7. Gomez-Brouchet, A., et al. 2001. Immunohistochemical assessment of human herpesvirus 8 infection in primary central nervous system large B cell lymphomas. *J. Clin. Pathol.* 54: 617-618.
8. Platt, G., et al. 2002. p16INK4a loss and sensitivity in KSHV associated primary effusion lymphoma. *Oncogene* 21: 1823-1831.
9. Krishnan, H.H., et al. 2004. Concurrent expression of latent and a limited number of lytic genes with immune modulation and antiapoptotic function by Kaposi's sarcoma-associated herpesvirus early during infection of primary endothelial and fibroblast cells and subsequent decline of lytic gene expression. *J. Virol.* 78: 3601-3620.

## SOURCE

KSHV ORF 72 (vR-15) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an internal region of KSHV of human herpesvirus 8 origin.

## RESEARCH USE

For research use only, not for use in diagnostic procedures.

## PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-19415 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

## APPLICATIONS

KSHV ORF 72 (vR-15) is recommended for detection of Kaposi's sarcoma-associated herpes virus (KSHV) ORF 72 of KSHV origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

## RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048.

## STORAGE

Store at 4° C, **\*\*DO NOT FREEZE\*\***. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

## PROTOCOLS

See our web site at [www.scbt.com](http://www.scbt.com) or our catalog for detailed protocols and support products.